«123»Seite
3 Artikel mit Literatur, Seite 2 von 3

MEDIZIN: Die Übersicht

Morbus Basedow: Neuester Stand zur Pathogenese, Diagnostik und Therapie

Dtsch Arztebl 1996; 93(42): A-2690 / B-2293 / C-2156

Heufelder, E.; Hofbauer, C.; Hörmann, Rudolf

1.Allanic H, Fauchet R, Orgiazzi J et al: Antithyroid drugs and Graves' disease. A prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679
2.Arscott P, Rosen ED, Koenig RJ: Immunoreactivity of Yersinia enterocolitica antigens in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 1992; 75: 295-300
3.Bahn RS, Dutton CM, Heufelder AE, Sarkar G: A genomic point mutation in the extracellular domain of the TSH receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994; 78: 256-260
4.Barlow ABT, Wheatcroft N, Watson P, Weetman AP: Association of HLA-DQA1*0501 with Graves' disease in English Caucasian men and women. Clin Endocrinol 1996; 44: 73-78
5.Bartalena L, Marocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A: Use of corticosteroids to prevent progression of Grave's ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-1352
6.Costagliola S, Swillens S, Niccoli P, Dumont JE, Vassart G, Ludgate M: Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. J Clin Endocrinol Metab 1992; 75: 1540-1544
7.Davies TF, Martin A, Concepcion ES: Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med 1991; 325: 238-44
8.DeGroot LJ, Quintans J: The causes of autoimmune thyroid disease. Endocr Rev 1989; 10: 537-562
9.Diamond T, Vine J, Smart R, Butler P: Thyrotoxic bone disease in women: a potentially reversible disease. Ann Int Med 1994; 120: 8-11
10.Endo T, Ohmori M, Ikeda M, Anzai E, Onaya T: Heterogeneous responses of recombinant human thyrotropin receptor to immunoglobulins from patients with Graves' disease. Biochem Biophys Res Comm 1992; 186: 1391-1396
11.Farrar JJ, Toft AD, Farrar JJ, Toft AD: Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol 1991; 35: 207-212
12.Feldt-Rasmussen U, Schleusener H, Carayon P: Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission of medical therapy for Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-103
13.Hashizume K, Ichikawa K, Sakurai A et al: Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-53
14.Hedley AJ, Young RE, Jones SJ, Alexancer WD, Bewsher PD: Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease. Long-term follow-up of 434 patients. Clin Endocrinol 1989; 31: 209-218
15.Heldin NE, Gustavsson B, Westermark K, Westermark B: A somatic point mutation in a putative ligand binding domain of the TSH receptor in a patient with autoimmune hyperthyroidism. J Clin Endocrinol Metab 1991; 73: 1374-6
16.Hoermann R, Schumm-Draeger PM, Mann K: Inhibition of functional and immunological responses to thyroid-stimulating antibodies from patients with Graves' disease by blockade of the thyrotropin receptor. Thyroid 1993; 3: 273-8
17.Hunt N, Willey KP, Jähner D: Multiple forms of thyroid stimulating hormone receptor associated with Graves' disease. Exp Clin Endocrinol 1992; 100: 22-27
18.Kosugi S, Ban T, Akamizu T, Kohn LD: Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors. Mol Endocrinol 1992; 6: 168-180
19.Luo GL, Fan JF, Seetharamaiah GS: Immunization of mice with Yersinia enterocolitica leads to the induction of antithyrotropin receptor antibodies. J Immunol 1993; 151: 922-928
20.Mann K, Dralle H, Gärtner R, Grußendorf M, Grüthers-Kießlich A, Meng W, von zur Mühlen, A, Reiners C: Schilddrüse, Rationelle Therapie in der Endokrinologie einschließlich Diabetes und Stoffwechsel, Thieme- Verlag 1996 (im Druck)
21.McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A: Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-224
22.Nagayama Y, Rapoport B: The thyrotropin receptor 25 years after its discovery - new insights after its molecular cloning. Mol Endocrinol 1992; 6: 145-156
23.Prummel MF, Wiersinga WM: Smoking and risk of Graves' disease. J Am Med Assoc 1993; 269: 479-482
24.Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R: Influence of abnormal thyroid function on the severity of accompanying Graves' ophthalmopathy. Arch Int Med 1990; 150: 1098-1101
25.Prummel MF, Wiersinga WM, Mourits M P: Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol 1989; 121 (Suppl. 2): 185-189
26.Reiners C: Radiojodtherapie. Indikation, Durchführung und Risiken. Dt Ärztebl 1993; B2217-B2221
27.Reinwein D, Benker G, Lazarus JH, Alexander WD, and the European Multicenter Study Group on antithyroid drug treatment. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993; 76: 1516-1521
28.Reinwein D, Röher H-D, Emrich D: Therapie der Hyperthyreose: Aktueller Stand. Dtsch med Wschr 1993; 118: 1036-1043
29.Romaldini JH, Bromberg N, Werner RS et al: Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 563-570
30.Rosch P J: Stressful life events and Graves' disease. Lancet 1993; 342: 566-567
31.Schleusener H, Peters H, Fischer C, Bogner U, Finke R, Kotulla P: Ist eine Verlaufsprognose nach thyreostatischer Behandlung bei Basedow-Hyperthyreose möglich? Akt Endokr Stoffw 1992; 13: 47-52
32.Sonino N, Girelli ME, Boscaro M: Life events in the pathogenesis of Graves' disease: a controlled study. Acta Endocrinol 1993; 128: 293-296
33.Springer TA: Adhesion receptors of the immune system. Nature 1990; 346: 425-434
34.Tallstedt L, Lundell G, Torring O et al: Occurrence of ophthalmopathy after treatment for Graves' disease hyperthyroidism. N Engl J Med 1992; 326: 1733-1738
35.Tamura K, Woo J, Murase N, Carrieri G, Nalesnik MA, Thomson AW: Suppression of autoimmune thyroid disease by FK 506; influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production. Clin Exp Immunol 1993; 91: 368-375
36.Tomer Y, Davies TF: Infection, thyroid disease, and autoimmunity. Endocr Rev 1993; 14: 107-120
37.Weetman AP, McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15: 778-830
38.Westphal SA: Seasonal variation in the diagnosis of Graves' disease. Clin Endocrinol 1994; 41: 27-30
39.Winsa B, Adami HO, Berstrom R: Stressful life events and Graves' disease. Lancet 1991; 338: 1475-1479
40.Yanagawa T, Mangklabruks A, DeGroot LJ: Strong association between HLA-DQA1*0501 and Graves' disease in a male Caucasian population. J Clin Endocrinol Metab 1994; 79: 227-229
«123»Seite
3 Artikel mit Literatur, Seite 2 von 3

Login

E-Mail

Passwort


Passwort vergessen?

Registrieren

Eingeloggt als

Suchen in